SOPHiA GENETICS: Muken proposes $79.4K share sale
The securities to be sold were acquired upon restricted stock unit vesting on October 2 and October 3, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
SOPHiA GENETICS SA is named as issuer for Ross J. Muken's proposed sale of 9,838 common shares, with an approximate sale date of October 5, 2026. The reported aggregate market value is $79,392.66, and Morgan Stanley Smith Barney LLC is named as broker. The shares were acquired upon vesting of restricted stock units on October 2 and October 3, 2026.
Key Figures
Key Terms
Rule 144 regulatory
Restricted Stock Units financial
10b5-1 Sales financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What prior SOPH sales by Ross J. Muken are listed?
AI-generated analysis. How Rhea-AI works. Not financial advice.